Investors relations | 2007 Key figures

2007
(EUR'000)

Sales and services

213,849

Gross margin

69,845

REBITDA (1)

18,269

REBIT (2)

11,788

Net profit (loss)

13,846

Equity

141,481

Net cash position

32,028

Current liabilities

118,658

Total assets

324,438

Return on equity

9.8%

Return on capital employed (ROCE)

5.7%

Share price at December 31 (Euro)

19.00

Number of shares

25,800,252

Market Capitalization

490,205

Earnings per share (EPS) - (Euro per share)

0.54

Enterprise value

458,177

EV/REBITDA

25.1

EMPLOYEES AT DECEMBER 31

1,360

(1) REBITDA: Recurring earnings before interest, taxes, depreciation, and amortization.
(2) REBIT: Recurring earnings before interest and taxes.

Download the IBA
Annual Report 2007

Download the IBA
Corporate Brochure

IBA Press Releases

Dec 18, 08
IBA Group

IBA receives FDA approval for its Pencil Beam Scanning

Read it in : english - french - dutch -

Dec 02, 08
IBA Group

IBA opens a new radiopharmaceuticals production center in Dallas, Texas

Read it in : english - french - dutch -

Dec 01, 08
IBA Group

IBA expands network via agreement with Biotech Cyclotron of Texas

Read it in : english - french - dutch -

| Read more news |

Sales and operating results by business unit

2007
(EUR'000)

Sales

Molecular Imaging

78,265

Proton Therapy

59,343

Dosimetry

35,240

Other Accelerators

41,001

Recurring operational profit/(loss)

Molecular Imaging

3,205

Technology & Equipment

8,583

Sales trends

Sales trends
by geographic sector

Change in number of employees and employee distribution
worldwide